Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model

Pedro J. Ramírez, Selwyn M. Vickers, Hidetaka A. Ono, Julia Davydova, Koichi Takayama, Timothy C. Thompson, David T. Curiel, Kirby I. Bland, Masato Yamamoto

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The full realization of the therapeutic potential of conditionally replicative adenoviruses (CRAds) in the field of pancreatic cancer has been hindered by limited tumor transduction and suboptimal replication control. Methods: We optimized infectivity enhancements and tumor-specific promoters (tsps) for pancreatic cancer. Infectivity was enhanced both by incorporating an RGD motif and by substituting the knob region with Ad serotype 3 knob (Ad5/Ad3). An optimized CRAd was tested in an orthotopic pancreatic cancer model by systemic administration. Results: Among a panel of 8 tsps, the 1.5-kb cyclooxygenase-2 (Cox-2L) promoter profile was most advantageous in the pancreatic cancer cell lines, whereas 4 more promoters were also promising. An infectivity-enhanced Ad5/Ad3 CRAd controlled with Cox-2L promoter was found to safely exhibit replication within a tumor in this model and was found to suppress tumor growth after systemic delivery. Conclusions: The infectivity-enhanced, promoter-controlled CRAd promises useful clinical applications for pancreatic cancer gene therapy.

Original languageEnglish (US)
Pages (from-to)481-490
Number of pages10
JournalAmerican Journal of Surgery
Volume195
Issue number4
DOIs
StatePublished - Apr 1 2008

Fingerprint

Pancreatic Neoplasms
Heterografts
Adenoviridae
Carcinogens
Neoplasms
Neoplasm Genes
Cyclooxygenase 2
Genetic Therapy
Cell Line
Growth
Therapeutics

Keywords

  • Conditionally replicative adenovirus
  • Fiber modification
  • Gene therapy
  • Orthotopic cancer model
  • Pancreatic cancer
  • Tumor-specific promoter

ASJC Scopus subject areas

  • Surgery

Cite this

Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. / Ramírez, Pedro J.; Vickers, Selwyn M.; Ono, Hidetaka A.; Davydova, Julia; Takayama, Koichi; Thompson, Timothy C.; Curiel, David T.; Bland, Kirby I.; Yamamoto, Masato.

In: American Journal of Surgery, Vol. 195, No. 4, 01.04.2008, p. 481-490.

Research output: Contribution to journalArticle

Ramírez, Pedro J. ; Vickers, Selwyn M. ; Ono, Hidetaka A. ; Davydova, Julia ; Takayama, Koichi ; Thompson, Timothy C. ; Curiel, David T. ; Bland, Kirby I. ; Yamamoto, Masato. / Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. In: American Journal of Surgery. 2008 ; Vol. 195, No. 4. pp. 481-490.
@article{fc7ee0a02c0c4905a0b5849906302831,
title = "Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model",
abstract = "Background: The full realization of the therapeutic potential of conditionally replicative adenoviruses (CRAds) in the field of pancreatic cancer has been hindered by limited tumor transduction and suboptimal replication control. Methods: We optimized infectivity enhancements and tumor-specific promoters (tsps) for pancreatic cancer. Infectivity was enhanced both by incorporating an RGD motif and by substituting the knob region with Ad serotype 3 knob (Ad5/Ad3). An optimized CRAd was tested in an orthotopic pancreatic cancer model by systemic administration. Results: Among a panel of 8 tsps, the 1.5-kb cyclooxygenase-2 (Cox-2L) promoter profile was most advantageous in the pancreatic cancer cell lines, whereas 4 more promoters were also promising. An infectivity-enhanced Ad5/Ad3 CRAd controlled with Cox-2L promoter was found to safely exhibit replication within a tumor in this model and was found to suppress tumor growth after systemic delivery. Conclusions: The infectivity-enhanced, promoter-controlled CRAd promises useful clinical applications for pancreatic cancer gene therapy.",
keywords = "Conditionally replicative adenovirus, Fiber modification, Gene therapy, Orthotopic cancer model, Pancreatic cancer, Tumor-specific promoter",
author = "Ram{\'i}rez, {Pedro J.} and Vickers, {Selwyn M.} and Ono, {Hidetaka A.} and Julia Davydova and Koichi Takayama and Thompson, {Timothy C.} and Curiel, {David T.} and Bland, {Kirby I.} and Masato Yamamoto",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.amjsurg.2007.04.014",
language = "English (US)",
volume = "195",
pages = "481--490",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model

AU - Ramírez, Pedro J.

AU - Vickers, Selwyn M.

AU - Ono, Hidetaka A.

AU - Davydova, Julia

AU - Takayama, Koichi

AU - Thompson, Timothy C.

AU - Curiel, David T.

AU - Bland, Kirby I.

AU - Yamamoto, Masato

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: The full realization of the therapeutic potential of conditionally replicative adenoviruses (CRAds) in the field of pancreatic cancer has been hindered by limited tumor transduction and suboptimal replication control. Methods: We optimized infectivity enhancements and tumor-specific promoters (tsps) for pancreatic cancer. Infectivity was enhanced both by incorporating an RGD motif and by substituting the knob region with Ad serotype 3 knob (Ad5/Ad3). An optimized CRAd was tested in an orthotopic pancreatic cancer model by systemic administration. Results: Among a panel of 8 tsps, the 1.5-kb cyclooxygenase-2 (Cox-2L) promoter profile was most advantageous in the pancreatic cancer cell lines, whereas 4 more promoters were also promising. An infectivity-enhanced Ad5/Ad3 CRAd controlled with Cox-2L promoter was found to safely exhibit replication within a tumor in this model and was found to suppress tumor growth after systemic delivery. Conclusions: The infectivity-enhanced, promoter-controlled CRAd promises useful clinical applications for pancreatic cancer gene therapy.

AB - Background: The full realization of the therapeutic potential of conditionally replicative adenoviruses (CRAds) in the field of pancreatic cancer has been hindered by limited tumor transduction and suboptimal replication control. Methods: We optimized infectivity enhancements and tumor-specific promoters (tsps) for pancreatic cancer. Infectivity was enhanced both by incorporating an RGD motif and by substituting the knob region with Ad serotype 3 knob (Ad5/Ad3). An optimized CRAd was tested in an orthotopic pancreatic cancer model by systemic administration. Results: Among a panel of 8 tsps, the 1.5-kb cyclooxygenase-2 (Cox-2L) promoter profile was most advantageous in the pancreatic cancer cell lines, whereas 4 more promoters were also promising. An infectivity-enhanced Ad5/Ad3 CRAd controlled with Cox-2L promoter was found to safely exhibit replication within a tumor in this model and was found to suppress tumor growth after systemic delivery. Conclusions: The infectivity-enhanced, promoter-controlled CRAd promises useful clinical applications for pancreatic cancer gene therapy.

KW - Conditionally replicative adenovirus

KW - Fiber modification

KW - Gene therapy

KW - Orthotopic cancer model

KW - Pancreatic cancer

KW - Tumor-specific promoter

UR - http://www.scopus.com/inward/record.url?scp=40949083068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949083068&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2007.04.014

DO - 10.1016/j.amjsurg.2007.04.014

M3 - Article

C2 - 18361926

AN - SCOPUS:40949083068

VL - 195

SP - 481

EP - 490

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 4

ER -